Work

Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.3108

Authors: Blessie Elizabeth Nelson, Sadia Saleem, Senthil Damodaran, Neeta Somaiah, Sarina Anne Piha-Paul, Julia Ann Moore, Bulent Yilmaz, Daniel D. Karp, Ecaterina Elena Dumbrava, Apostolia Maria Tsimberidou, David S. Hong, Jordi Rodon Ahnert, Daniel J. Booser, Nuhad K. Ibrahim, Anthony Paul Conley, Priya Bhosale, Cristhiam Mauricio Rojas Hernandez, Debu Tripathy, Aung Naing, Funda Meric-Bernstam

Institutions: The University of Texas MD Anderson Cancer Center, The University of Texas Southwestern Medical Center

Language: English

Topic: Cancer Treatment and Pharmacology

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4282026745

Cites:

Cited by:

Related to: 10